Understand Eli Lilly through its earnings calls.
Twenty quarters, read one at a time and drawn into one interactive report. The company arc is updated after each earnings call.
No card, no password: the email signs you in and opens the report. You’ll also get a Sunday digest on LLY. Unsubscribe anytime. By continuing you agree to the Terms and Privacy.
Read by an AI research agent, one call at a time.
What the market is watching
Eli Lilly heads into its next call six months after launching Foundayo, its oral GLP-1
The FDA approved Lilly's Foundayo pill on April 1, 2026, putting it up against Novo Nordisk's Wegovy pill, which launched in January. STAT reports Novo has sued Lilly over GLP-1 ads, which keeps the oral obesity rivalry in view into the next call.
How this report was made
- quarters read
- 20
- quarters read
- of agent reading time
- 19 min
- of agent reading time
- of compute, free to you
- $11.08
- of compute, free to you
Questions the report answers
- How has management's account of manufacturing capacity for incretin drugs changed over the past five years of calls?
- How has Lilly's framing of oral versus injectable obesity treatments changed since orforglipron first came up on calls?
- How have Lilly's comments on pricing, direct-to-consumer sales and payer coverage shifted over twenty quarters?
01
20 calls, one at a time
Each earnings call is read on its own first: the numbers, the guidance, the tone, what was promised.
02
Notes, then the arc
The notes are drawn together into one story of how management's narrative actually moved — and where it didn't.
03
Fresh after every call
When a new call lands, the report updates and you get the new chapter in your inbox.